LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.17

+2.1%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$224.65M
EPS-2.8500
P/E Ratio-2.51
Earnings Date07/29/2026

lenz

Other Non-Current Assets

Last Annual Value

13.53M

3-Year CAGR

659%

5-Year CAGR

%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Other Non-Current Assets

LENZ · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.53M
69.9%483.5%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
84.00K
-39.9%-19.7%-4.3%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
2.92M
170.4%72.6%22.8%
25.84M
218.3%307.5%N/A
130.00K
N/A16.3%-36.7%
8.10M
19.9%11.0%N/A
192.14M
174.2%113.3%N/A
14.69M
1.0%-1.2%N/A
10.27M
19.4%79.3%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.165, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.165